Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:3543004rdf:typepubmed:Citationlld:pubmed
pubmed-article:3543004lifeskim:mentionsumls-concept:C0086418lld:lifeskim
pubmed-article:3543004lifeskim:mentionsumls-concept:C1521991lld:lifeskim
pubmed-article:3543004lifeskim:mentionsumls-concept:C1519249lld:lifeskim
pubmed-article:3543004lifeskim:mentionsumls-concept:C0475264lld:lifeskim
pubmed-article:3543004lifeskim:mentionsumls-concept:C0376315lld:lifeskim
pubmed-article:3543004lifeskim:mentionsumls-concept:C0301817lld:lifeskim
pubmed-article:3543004lifeskim:mentionsumls-concept:C0037791lld:lifeskim
pubmed-article:3543004lifeskim:mentionsumls-concept:C0599573lld:lifeskim
pubmed-article:3543004lifeskim:mentionsumls-concept:C0016349lld:lifeskim
pubmed-article:3543004pubmed:issue3lld:pubmed
pubmed-article:3543004pubmed:dateCreated1987-3-4lld:pubmed
pubmed-article:3543004pubmed:abstractTextA human pituitary-derived serine protease, immunologically identical to human lung tryptase (Smith, T. J., Hougland, M.W., and Johnson, D.A. (1984) J. Biol. Chem. 259, 11046-11051), was found immunohistochemically to be associated with mast cells present in pituitary connective tissue. Western blotting combined with sodium dodecyl sulfate-polyacrylamide gel electrophoresis indicated the presence of multiple forms: a major Mr 36,300 form and three minor forms with Mr 32,400, 33,400, and 34,600. Two major forms with Mr 35,600 and 34,100 were detected by affinity labeling with 125I-D-Tyr-Glu-Phe-Lys-Arg-CH2Cl. Treatment of the pituitary tryptase preparation with N-glycosidase F indicated that some of the molecular weight heterogeneity results from N-linked glycosylation. The multiple molecular weight forms appear to have the same NH2-terminal sequence: Ile-Val-Gly-Gly-Gln-Glu-Ala-Pro. Pituitary tryptase has an apparent Mr = 110,000 by gel filtration on Sephadex G-200 in the presence of 0.3 M NaCl, indicating that the enzyme may be a tetramer of Mr = 32,400-36,300 subunits. However, this quaternary structure was not stable to gradient polyacrylamide gel electrophoresis. Human pituitary tryptase was so reactive toward synthetic tripeptide coumarin-containing substrates containing a pair of basic amino acids at the site of cleavage such as benzyloxylcarbonyl-L-Ala-L-Lys-L-Arg-4-methylcoumarin-7-amide (k cat/Km = 2.38 X 10(8) M-1 s-1) that Briggs-Haldane kinetics may apply. The reversible inhibitor NaCl at a concentration of 1 M decreased the k cat/Km for benzyloxylcarbonyl-L-Ala-L-Lys-L-Arg-4-methylcoumarin-7-amide to 6.53 X 10(6) M-1 s-1, which reflected a 100-fold increase in apparent Km. Based on active site titration with fluorescein mono-p-guanidinobenzoate hydrochloride, NaCl had no effect on the number of accessible active sites. Substrate specificity studies with prohormones indicated that pituitary tryptase has a preference for cleaving COOH-terminal to arginine or lysine residues which are preceded by a proline residue 4 or 6 residues NH2-terminal to the site of cleavage.lld:pubmed
pubmed-article:3543004pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3543004pubmed:languageenglld:pubmed
pubmed-article:3543004pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3543004pubmed:citationSubsetIMlld:pubmed
pubmed-article:3543004pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3543004pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3543004pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3543004pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3543004pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3543004pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3543004pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3543004pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3543004pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3543004pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3543004pubmed:statusMEDLINElld:pubmed
pubmed-article:3543004pubmed:monthJanlld:pubmed
pubmed-article:3543004pubmed:issn0021-9258lld:pubmed
pubmed-article:3543004pubmed:authorpubmed-author:JohnsonD ADAlld:pubmed
pubmed-article:3543004pubmed:authorpubmed-author:SeidahN GNGlld:pubmed
pubmed-article:3543004pubmed:authorpubmed-author:ChrétienMMlld:pubmed
pubmed-article:3543004pubmed:authorpubmed-author:HamelinJJlld:pubmed
pubmed-article:3543004pubmed:authorpubmed-author:Marcinkiewicz...lld:pubmed
pubmed-article:3543004pubmed:authorpubmed-author:CromlishJ AJAlld:pubmed
pubmed-article:3543004pubmed:issnTypePrintlld:pubmed
pubmed-article:3543004pubmed:day25lld:pubmed
pubmed-article:3543004pubmed:volume262lld:pubmed
pubmed-article:3543004pubmed:ownerNLMlld:pubmed
pubmed-article:3543004pubmed:authorsCompleteYlld:pubmed
pubmed-article:3543004pubmed:pagination1363-73lld:pubmed
pubmed-article:3543004pubmed:dateRevised2007-11-14lld:pubmed
pubmed-article:3543004pubmed:meshHeadingpubmed-meshheading:3543004-...lld:pubmed
pubmed-article:3543004pubmed:meshHeadingpubmed-meshheading:3543004-...lld:pubmed
pubmed-article:3543004pubmed:meshHeadingpubmed-meshheading:3543004-...lld:pubmed
pubmed-article:3543004pubmed:meshHeadingpubmed-meshheading:3543004-...lld:pubmed
pubmed-article:3543004pubmed:meshHeadingpubmed-meshheading:3543004-...lld:pubmed
pubmed-article:3543004pubmed:meshHeadingpubmed-meshheading:3543004-...lld:pubmed
pubmed-article:3543004pubmed:meshHeadingpubmed-meshheading:3543004-...lld:pubmed
pubmed-article:3543004pubmed:meshHeadingpubmed-meshheading:3543004-...lld:pubmed
pubmed-article:3543004pubmed:meshHeadingpubmed-meshheading:3543004-...lld:pubmed
pubmed-article:3543004pubmed:meshHeadingpubmed-meshheading:3543004-...lld:pubmed
pubmed-article:3543004pubmed:meshHeadingpubmed-meshheading:3543004-...lld:pubmed
pubmed-article:3543004pubmed:meshHeadingpubmed-meshheading:3543004-...lld:pubmed
pubmed-article:3543004pubmed:meshHeadingpubmed-meshheading:3543004-...lld:pubmed
pubmed-article:3543004pubmed:meshHeadingpubmed-meshheading:3543004-...lld:pubmed
pubmed-article:3543004pubmed:meshHeadingpubmed-meshheading:3543004-...lld:pubmed
pubmed-article:3543004pubmed:meshHeadingpubmed-meshheading:3543004-...lld:pubmed
pubmed-article:3543004pubmed:meshHeadingpubmed-meshheading:3543004-...lld:pubmed
pubmed-article:3543004pubmed:meshHeadingpubmed-meshheading:3543004-...lld:pubmed
pubmed-article:3543004pubmed:meshHeadingpubmed-meshheading:3543004-...lld:pubmed
pubmed-article:3543004pubmed:meshHeadingpubmed-meshheading:3543004-...lld:pubmed
pubmed-article:3543004pubmed:meshHeadingpubmed-meshheading:3543004-...lld:pubmed
pubmed-article:3543004pubmed:year1987lld:pubmed
pubmed-article:3543004pubmed:articleTitleHuman pituitary tryptase: molecular forms, NH2-terminal sequence, immunocytochemical localization, and specificity with prohormone and fluorogenic substrates.lld:pubmed
pubmed-article:3543004pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:3543004pubmed:publicationTypeComparative Studylld:pubmed
pubmed-article:3543004pubmed:publicationTypeResearch Support, U.S. Gov't, P.H.S.lld:pubmed
pubmed-article:3543004pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:3543004lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:3543004lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:3543004lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:3543004lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:3543004lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:3543004lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:3543004lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:3543004lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:3543004lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:3543004lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:3543004lld:pubmed